
|Videos|July 13, 2017
Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC
Author(s)Brian Rini, MD
Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.
Advertisement
Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5


















